PSMA-PET/CT can act as a prognostic tool for long-term response assessment—Grubmüller et al found TTV measured using modified PERCIST to correlate with PSA response and OS, whereas conventional RECIST1.1 criteria based on anatomical tumour size did not reliably predict outcomes. The gene discussed is FOLH1; the disease is neoplasm.